Improved real‐world glycaemic outcomes with liraglutide versus other incretin‐based therapies in type 2 diabetes

Abstract

In clinical practice, LIRA was associated with significantly greater reductions in A1C and improved glycaemic goal attainment compared with either EXEN or SITA among adult patients with T2D.

Real-world comparison of treatment patterns and effectiveness of albiglutide and liraglutide

“…In a real-world analysis, our finding in the subset analysis of patients with baseline and follow-up HbA 1c test results showed a −1.0% mean change in HbA 1c Research Article Buysman, Sikirica, Thayer, Bogart, DuCharme & Joshi in both the albiglutide and liraglutide cohorts. This finding was also similar to that observed in another real-world analysis of liraglutide (HbA 1c change from baseline −1.08% [27]) during a postindex period of the same duration. The differences in HbA 1c outcomes between the albiglutide and liraglutide cohorts after 6 months of follow-up were not significantly different in this study.…”

Liraglutide for Type 2 diabetes and obesity: a 2015 update

“…An extensive clinical trial program (see Section 'Pharmacokinetic properties of liraglutide') and evidence from the real-world clinical practice setting [113,114] have firmly established the efficacy of liraglutide both as monotherapy and as add-on therapy compared with other antidiabetic agents. Thus, liraglutide 1.2 and 1.8 mg daily monotherapy or add-on therapy to one or more OADs improved glycemic control, body weight and SBP to a significant greater extent than placebo monotherapy or add-on therapy.…”

Liraglutide: A Review of Its Use in Adult Patients with Type 2 Diabetes Mellitus

“…For example, in a large retrospective cohort study of a US claims database, patients who initiated treatment with liraglutide (n = 234) achieved significantly greater reductions in adjusted mean HbA 1c than those initiating treatment with exenatide (n = 182) or sitagliptin (n = 1,757) after 6 months [47], providing support for evidence from clinical trials (see Sects. 4.1 and 4.2).…”

“…The mean adjusted reduction from baseline in HbA 1c in liraglutide recipients was 1.1 % compared with 0.7 % in the sitagliptin group (p \ 0.0001) and 0.8 % in the exenatide group (p \ 0.001). After adjusting for confounding factors, the likelihood of achieving a target HbA 1c of \7 % was also significantly (p \ 0.05) higher with liraglutide than with exenatide or sitagliptin treatment [47]. This evidence is supported by a UK retrospective, database study of adult patients treated with liraglutide (n = 294) or sitagliptin (n = 2,790) [43] and the French 2-year postmarketing EVIDENCE study (n = 3,152) [51,52].…”

“…Liraglutide, typically as add-on therapy, provided effective glycaemic control in adult patients with type 2 diabetes in the real-world clinical practice setting, based on several large retrospective [43][44][45][46][47][48] or postmarketing [49][50][51][52] analyses conducted in the USA [44,47,50], UK [43,45], France [51,52], Israel [46], India [49] or country not specified [48]; data for most studies are available as abstract presentations [43][44][45][48][49][50][51][52]. For example, in a large retrospective cohort study of a US claims database, patients who initiated treatment with liraglutide (n = 234) achieved significantly greater reductions in adjusted mean HbA 1c than those initiating treatment with exenatide (n = 182) or sitagliptin (n = 1,757) after 6 months [47], providing support for evidence from clinical trials (see Sects.…”